STOCK TITAN

Caribou Biosciences, Inc. - CRBU STOCK NEWS

Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.

Caribou Biosciences, Inc. (CRBU) is a clinical-stage biotechnology company pioneering advancements in genome engineering. Leveraging revolutionary CRISPR-Cas9 technology, Caribou specializes in developing innovative cellular engineering solutions. Their technology, which pairs Cas9 with guide RNA to facilitate precise DNA modifications, is being harnessed for sophisticated gene knock-outs and knock-ins. Caribou's tools provide transformative capabilities across various sectors, including biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

At the forefront of biopharmaceutical innovation, Caribou is dedicated to applying its proprietary CRISPR hybrid RNA-DNA (chRDNA) platform to create next-generation genome-edited cell therapies. Their pipeline includes allogeneic CAR-T and CAR-NK cell therapies, aimed at treating patients with hematologic malignancies and solid tumors.

Recent milestones include the FDA's feedback on a Phase 3 trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy targeting large B cell lymphoma (LBCL). The ongoing ANTLER Phase 1 trial has shown promising results, with CB-010 receiving Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations. Caribou is also expanding CB-010's potential application to lupus nephritis and extrarenal lupus, with a GALLOP Phase 1 trial planned for late 2024.

Financially, Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2026. Their strategic partnerships, including a collaboration with Pfizer, have bolstered their financial standing.

Caribou continues to push the boundaries of genome editing with its chRDNA technology, significantly improving the precision of genome edits. Their commitment to transforming patient lives through cutting-edge science positions them as a leader in the biotech landscape.

Rhea-AI Summary
Caribou Biosciences, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced the appointment of Tim Kelly as the chief technology officer. Caribou highlighted the successful execution across its allogeneic CAR-T cell therapy platform and provided an outlook on multiple clinical catalysts planned for 2024. The company reported significant clinical highlights and corporate accomplishments in 2023, along with the anticipated milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) has received positive feedback from the FDA on its Phase 3 randomized controlled trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy for second-line relapsed or refractory large B cell lymphoma. The FDA has accepted Caribou's proposed comparator arm of immunochemotherapy followed by high dose chemotherapy and autologous stem cell transplantation. The ongoing ANTLER Phase 1 trial is progressing well, with plans to report initial dose expansion data and the recommended Phase 2 dose for CB-010 in Q2 2024. Caribou aims to initiate a Phase 3 pivotal trial by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
-
Rhea-AI Summary
CRBU Caribou Biosciences, Inc. reports progress in ANTLER Phase 1 trial and plans to share FDA feedback by year-end 2023. $396.7 million in cash expected to fund operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
Rhea-AI Summary
Caribou Biosciences, Inc. has appointed Dr. Sundar Jagannath to its scientific advisory board. Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma. He will provide guidance to Caribou as they advance the CaMMouflage Phase 1 trial for CB-011, their allogeneic anti-BCMA CAR-T cell therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.11%
Tags
management
-
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) will be participating in several investor conferences, including Truist Securities BioPharma Symposium on November 9, Jefferies London Healthcare Conference on November 15, and 6th Annual Evercore ISI HealthCONx Conference on November 30. Webcasts of the events will be available on Caribou's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
conferences
-
Rhea-AI Summary
Caribou Biosciences receives FDA clearance for its allogeneic anti-CLL-1 CAR-T cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
Rhea-AI Summary
Caribou Biosciences appoints Reigin Zawadzki as chief people officer to lead people strategy and maintain strong culture. Aim to position for future commercialization. Zawadzki brings 20 years of experience in biotechnology HR. Positive for employee experiences and diversity. No specific numbers mentioned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
management
-
Rhea-AI Summary
Caribou Biosciences, Inc. to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences
-
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported positive financial results for Q2 2023 and recent business updates, including significant clinical advancements and an equity investment from Pfizer. With more than $400 million in cash, cash equivalents, and marketable securities, Caribou is well-positioned to fund its operations until Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
Rhea-AI Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) has announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a price of $6.50 per share. The gross proceeds to Caribou are expected to be approximately $125 million. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.6%
Tags

FAQ

What is the current stock price of Caribou Biosciences (CRBU)?

The current stock price of Caribou Biosciences (CRBU) is $1.8 as of December 20, 2024.

What is the market cap of Caribou Biosciences (CRBU)?

The market cap of Caribou Biosciences (CRBU) is approximately 163.4M.

What does Caribou Biosciences specialize in?

Caribou Biosciences specializes in genome engineering using CRISPR-Cas9 technology to develop innovative cellular engineering solutions.

What is CB-010?

CB-010 is Caribou's lead allogeneic anti-CD19 CAR-T cell therapy, currently in clinical trials for large B cell lymphoma and lupus.

What recent FDA feedback did Caribou receive?

The FDA provided feedback on a Phase 3 trial for CB-010, stating that the proposed comparator arm is acceptable.

How is Caribou's financial health?

Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash and equivalents, sufficient to fund operations into Q1 2026.

What is chRDNA technology?

chRDNA (CRISPR hybrid RNA-DNA) technology is Caribou's proprietary platform that allows for more precise genome editing compared to traditional methods.

What are the applications of Caribou's technology?

Applications include basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

What designations has CB-010 received from the FDA?

CB-010 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations.

What is the ANTLER trial?

The ANTLER trial is a Phase 1 clinical trial evaluating CB-010 in patients with large B cell lymphoma.

What is Caribou's collaboration with Pfizer?

Caribou's collaboration with Pfizer includes a $25 million equity investment, supporting their financial and developmental goals.

What upcoming trials are planned for CB-010?

Caribou plans to initiate the GALLOP Phase 1 trial for CB-010 in lupus nephritis and extrarenal lupus by the end of 2024.

Caribou Biosciences, Inc.

Nasdaq:CRBU

CRBU Rankings

CRBU Stock Data

163.45M
80.73M
10.04%
62.54%
8.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BERKELEY